Physician profile
Tatyana Kushner
NPI 1336463082
$180,535.55
in general payments reported to CMS, 2019-2025
18 companies · $51K in 2025
The $51K reported for 2025 was more than what 86% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $5,015 · 2021: $9,104 · 2022: $38K · 2023: $36K · 2024: $29K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $91K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $7,197 · Food and Beverage: $6,069 · Education: $59.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $90,915.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,520.00 |
| Travel and Lodging | $7,196.98 |
| Food and Beverage | $6,069.42 |
| Education | $59.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $117,216.13 | 2019-2025 | Vemlidy, Livdelzi, Epclusa |
| Glaxosmithkline, LLC. | $21,000.00 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $11,888.16 | 2024-2025 | Bylvay, Iqirvo |
| Abbvie INC. | $10,736.40 | 2021-2025 | |
| Mirum Pharmaceuticals, INC. | $7,820.00 | 2022-2025 | Livmarli |
| Madrigal Pharmaceuticals | $4,690.14 | 2025 | Rezdiffra |
| Ipsen Pharma Sas | $3,320.00 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,079.13 | 2022-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $235.97 | 2023 | |
| Novo Nordisk INC | $168.52 | 2023-2025 | |
| Eiger Biopharmaceuticals, INC. | $104.16 | 2023 | Zokinvy |
| Olympus America INC. | $102.12 | 2024 | Endoclot Phs |
| Janssen Scientific Affairs, LLC | $50.08 | 2025 | Tremfya |
| Lilly USA, LLC | $35.49 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.83 | 2025 | Entyvio |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orphalan INC | $32.64 | 2024 | Cuvrior |
| Dynavax Technologies Corporation | $21.78 | 2025 | Heplisav-B |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tatyana Kushner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.